Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Patients After Acute Coronary Syndrome
CTR20160002Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of alirocumab in acute coronary syndrome (ACS), coronary arteriosclerosis, hypercholesterolemia, sponsored by Sanofi. Started Feb 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on CTR20160002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160002.